Meditera Tibbi Malzeme Sanayi ve Ticaret AS Cash Flow-to-Debt Ratio
Meditera Tibbi Malzeme Sanayi ve Ticaret AS cash flow-to-debt ratio. Meditera Tibbi Malzeme Sanayi ve Ticaret AS (MEDTR) has a Cash Flow-to-Debt Ratio of 0.28x as of March 2026, meaning its operating cash flow of TL180.45 Million could theoretically repay 0% of its total liabilities (TL648.60 Million) in one year. Check cash flow quality index of Meditera Tibbi Malzeme Sanayi ve Ticaret to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Meditera Tibbi Malzeme Sanayi ve Ticaret AS (2018–2025)
Cash flow-to-debt ratio of Meditera Tibbi Malzeme Sanayi ve Ticaret AS from 2018 to 2025. Historical debt coverage capacity for Meditera Tibbi Malzeme Sanayi ve Ticaret AS across 8 annual periods. Check Meditera Tibbi Malzeme Sanayi ve Ticaret (MEDTR) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Meditera Tibbi Malzeme Sanayi ve Ticaret AS Cash Flow-to-Debt Ratio by Year (2018–2025)
Meditera Tibbi Malzeme Sanayi ve Ticaret AS cash flow-to-debt ratio by year from 2018 to 2025. Year-by-year debt coverage analysis for Meditera Tibbi Malzeme Sanayi ve Ticaret AS. For the full cash flow conversion analysis, see Meditera Tibbi Malzeme Sanayi ve Ticaret (MEDTR) cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (TRY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.66x | TL435.35 Million | TL661.10 Million | ▼ -36.5% |
| 2024 | 1.04x | TL780.69 Million | TL752.75 Million | ▼ -22.8% |
| 2023 | 1.34x | TL801.02 Million | TL596.54 Million | ▲ +5492.3% |
| 2022 | 0.02x | TL5.10 Million | TL212.41 Million | ▼ -90.2% |
| 2021 | 0.24x | TL36.64 Million | TL149.84 Million | ▼ -58.4% |
| 2020 | 0.59x | TL73.26 Million | TL124.53 Million | ▲ +175.6% |
| 2019 | 0.21x | TL20.01 Million | TL93.72 Million | ▼ -72.2% |
| 2018 | 0.77x | TL73.26 Million | TL95.36 Million | — |